Last reviewed · How we verify
Shinbaro Capsule
Shinbaro Capsule is a Small molecule drug developed by Green Cross Corporation. It is currently FDA-approved. Also known as: GCSB-5.
Shinbaro Capsule is a small molecule neurokinin 1 receptor antagonist used to treat conditions such as osteoarthritis and hand osteoarthritis. It is also known as Netupitant, a substance-P receptor antagonist.
At a glance
| Generic name | Shinbaro Capsule |
|---|---|
| Also known as | GCSB-5 |
| Sponsor | Green Cross Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule
- Efficacy of Shinabro in Hand Osteoarthritis (PHASE2, PHASE3)
- To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis (PHASE4)
- Efficacy and Safety of Shinbaro Capsule (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shinbaro Capsule CI brief — competitive landscape report
- Shinbaro Capsule updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about Shinbaro Capsule
What is Shinbaro Capsule?
Who makes Shinbaro Capsule?
Is Shinbaro Capsule also known as anything else?
What development phase is Shinbaro Capsule in?
Related
- Manufacturer: Green Cross Corporation — full pipeline
- Also known as: GCSB-5
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing